- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 27.07. | AstraZeneca execs 'very confident' in homegrown ADC pipeline despite scrapping 2 candidates | ||
| 25.07. | De-Risking a Rare Disease Launch Starts with Precision | ||
| 24.07. | Amgen sheds around 40 staffers amid continuing struggles | ||
| 24.07. | Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout | ||
| 24.07. | Scribe Therapeutics records upsized $129M IPO to bankroll lipid-lowering genetic meds | ||
| 23.07. | Scancell to go public after winning reverse merger bid for troubled Neuphoria | ||
| 23.07. | Lilly's triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear | ||
| 23.07. | Australian biopharma Clinuvel to shed up to 20% of workforce in move to US | ||
| 23.07. | Roche drops TCE for lupus, but hasn't given up on autoimmune cell therapies | ||
| 22.07. | Celldex ends skin disease program after failing phase 2 test | ||
| 22.07. | Royalty Pharma pens $425M deal for slice of sales on AstraZeneca's ATTR drug | ||
| 21.07. | Why Novartis CEO ended his ADC holdout for $1.5B Myricx deal | ||
| 21.07. | Jupiter enters psychedelics space with $100M deal for PharmAla's MDMA drug | ||
| 21.07. | Agios says adios to sickle cell program over lackluster phase 2 data | ||
| 21.07. | Indian generics maker Lupin seeds US spinout Kaveri with cash, clinical-phase cancer assets | ||
| 21.07. | Novartis drops phase 2 radioligand therapy, but CEO's commitment to modality 'unchanged' | ||
| 20.07. | BMS expands AI footprint with Nvidia, aiming for 'most powerful AI factory in life sciences' | ||
| 20.07. | Scribe Therapeutics aims for $96M IPO to fund clinical push for lipid-lowering genetic meds | ||
| 20.07. | Kolon's cell-based gene therapy fails phase 3 osteoarthritis trial | ||
| 17.07. | BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fields | ||
| 17.07. | Jasper Therapeutics finds new purpose in merger with Kira Pharmaceuticals, while offloading Tavneos rival to Mirador | ||
| 17.07. | 5 emerging biotech hubs | ||
| 17.07. | GSK axes key cough drug candidate after phase 3 data end blockbuster hopes | ||
| 17.07. | Dimerix snaps up Mission's stalled, phase 2-ready kidney disease candidate in $292M deal | ||
| 16.07. | Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trial |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.